

CORRECTION

Open Access



Correction to: The International/Canadian Hereditary Angioedema Guideline

Stephen Betschel^{1*}, Jacquie Badiou², Karen Binkley¹, Rozita Borici-Mazi³, Jacques Hébert⁴, Amin Kanani⁵, Paul Keith⁶, Gina Lacuesta⁷, Susan Wasserman⁶, Bill Yang⁸, Emel Ayyören-Pürsün⁹, Jonathan Bernstein¹⁰, Konrad Bork¹¹, Teresa Caballero¹², Marco Cicardi¹³, Timothy Craig¹⁴, Henriette Farkas¹⁵, Anete Grumach¹⁶, Connie Katelaris¹⁷, Hilary Longhurst¹⁸, Marc Riedl¹⁹, Bruce Zuraw¹⁹, Magdalena Berger²⁰, Jean-Nicolas Boursiquot²¹, Henrik Boysen²², Anthony Castaldo²³, Hugo Chapdelaine²⁴, Lori Connors⁷, Lisa Fu²⁵, Dawn Goodyear²⁶, Alison Haynes²⁷, Palinder Kamra²⁸, Harold Kim^{29,30}, Kelly Lang-Robertson¹, Eric Leith³¹, Christine McCusker³², Bill Moote³³, Andrew O'Keefe²⁷, Ibraheem Othman³⁴, Man-Chiu Poon³⁵, Bruce Ritchie³⁶, Charles St-Pierre³⁷, Donald Stark³⁸ and Ellie Tsai³⁹

Correction to: *Allergy Asthma Clin Immunol* (2019) 15:72 <https://doi.org/10.1186/s13223-019-0376-8>

Following the publication of this article [1], the authors requested to amend the characterisation of ‘lanadelumab’ from ‘humanised’ to the correct ‘fully human’.

Therefore, the fourth paragraph under Recommendation #24 should be amended to read:

“Lanadelumab (Takeda), a fully human monoclonal antibody against kallikrein, takes approximately 70 days to reach a steady state concentration [110], and is therefore not recommended for STP...”

Similarly, the first paragraph under Recommendation #27 should be amended to read:

“Lanadelumab is a subcutaneously injectable, fully human, anti-active plasma kallikrein monoclonal antibody (IgG1/κ-light chain)...”

The original article can be found online at <https://doi.org/10.1186/s13223-019-0376-8>.

*Correspondence: betschels@smh.ca

¹ University of Toronto, Toronto, ON, Canada

Full list of author information is available at the end of the article

Author details

¹ University of Toronto, Toronto, ON, Canada. ² HAE Canada, Notre Dame Des Lourdes, MB, Canada. ³ Department of Medicine, Queen's University, Kingston, ON, Canada. ⁴ Department of Medicine, Laval University, Quebec City, QC, Canada. ⁵ Division of Allergy and Clinical Immunology, St. Paul's Hospital, Department of Medicine, University of British Columbia, Vancouver, BC, Canada. ⁶ Department of Medicine, McMaster University, Hamilton, ON, Canada. ⁷ Department of Medicine, Dalhousie University, Halifax, NS, Canada. ⁸ University of Ottawa Medical School, Ottawa, ON, Canada. ⁹ Goethe-Universität Frankfurt am Main, Frankfurt Am Main, Germany. ¹⁰ Department of Internal Medicine, University of Cincinnati, Cincinnati, OH, USA. ¹¹ Department of Dermatology, University Hospital of the Johannes Gutenberg-University of Mainz, Mainz, Germany. ¹² Hospital La Paz Institute for Health Research, Madrid, Spain. ¹³ Department of Internal Medicine, Università degli Studi di Milano, Ospedale L. Sacco, Milan, Italy. ¹⁴ Departments of Medicine and Pediatrics, Penn State University, Hershey, PA, USA. ¹⁵ 3rd Department of Internal Medicine, Faculty of Medicine, Semmelweis University, Budapest, Hungary. ¹⁶ Laboratory of Clinical Immunology, Faculdade de Medicina ABC, Sao Paulo, Brazil. ¹⁷ Campbelltown Hospital, Western Sydney University, New South Wales, Australia. ¹⁸ ddenbrooke's Hospital, Cambridge and University College Hospital, London, England, UK. ¹⁹ University of California, San Diego, San Diego, CA, USA. ²⁰ Moncton Hospital, Moncton, NB, Canada. ²¹ Division of Allergy and Clinical Immunology, Centre Hospitalier Universitaire de Québec, Laval University, Quebec City, QC, Canada. ²² HAE International (HAEi), Horsens, Denmark. ²³ HAE International (HAEi), Fairfax, VA, USA. ²⁴ Institut de Recherches Cliniques de Montréal, Montreal, QC, Canada. ²⁵ Toronto Allergy Group, Toronto, ON, Canada. ²⁶ Southern Alberta Rare Blood and Bleeding Disorders Program, Foothills Medical Centre, University of Calgary, Calgary, AB, Canada. ²⁷ Division of Pediatrics, Faculty of Medicine, Memorial University, St John's, NF, Canada. ²⁸ Janeway Children's Health and Rehabilitation Centre, Memorial University, St John's, NF, Canada. ²⁹ Division of Clinical Immunology and Allergy, Department of Medicine, Western University, London, ON, Canada. ³⁰ Division of Clinical Immunology and Allergy, Department of Medicine, McMaster University, Hamilton, ON, Canada. ³¹ Department of Medicine, University of Toronto, Oakville, ON,



© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Canada.³² Department of Immunology, McGill University Health Centre, Montreal, QC, Canada. ³³ Department of Medicine, Western University, London, ON, Canada. ³⁴ College of Medicine, University of Saskatchewan, Regina, SK, Canada. ³⁵ Departments of Medicine, Pediatrics and Oncology, University of Calgary Cumming School of Medicine, Calgary, AB, Canada. ³⁶ Departments of Medicine and Medical Oncology, University of Alberta, Edmonton, AB, Canada. ³⁷ L'angio-oedème Hériditaire du Québec, Quebec City, QC, Canada. ³⁸ Department of Medicine, University of British Columbia, Vancouver, BC, Canada. ³⁹ Department of Internal Medicine, Queen's University, Kingston, ON, Canada.

Published online: 06 May 2020

Reference

1. Betschel S, Badiou J, Binkley K, Borici-Mazi R, Hébert J, Kanani A, Keith P, Lacuesta G, Waserman S, Yang B, Aygören-Pürsün E, Bernstein J, Bork K,

Caballero T, Cicardi M, Craig T, Farkas H, Grumach A, Katelaris C, Longhurst H, Riedl M, Zuraw B, Berger M, Boursiquot J-N, Boysen H, Castaldo A, Chapdelaine H, Connors L, Lisa F, Goodyear D, Haynes A, Kamra P, Kim H, Lang-Robertson K, Leith E, McCusker C, Moote B, O'Keefe A, Othman I, Poon M-C, Ritchie B, St-Pierre C, Stark D, Tsai E. The International/Canadian Hereditary Angioedema Guideline. *Allergy Asthma Clin Immunol.* 2019;15:72. <https://doi.org/10.1186/s13223-019-0376-8>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.